2025 marks a pivotal milestone for the global pharmaceutical industry. At this crucial juncture, GeneScience Pharmaceuticals (“GenSci”) will host its 2nd R&D Day and China Innovative Drug Summit on May 17 in Shanghai, bringing together over 200 experts to explore breakthroughs in basic research, clinical value translation, and globalization strategies—charting a roadmap for China’s innovative drug development.
The event will feature a morning plenary session and afternoon parallel sessions. Dr. Jin Lei, CEO and Chief Scientist of GenSci, along with senior executives, will unveil the company’s R&D strategy and latest progress. Principal investigators will present key Phase III clinical data for Jinbeixin® (Genakumab), followed by a discussion among industry leaders, clinical experts, and immunologists on the latest trends in rheumatology and immunology. The breakout sessions will use Genakumab as a case study to illustrate the journey from discovery to commercialization, covering three critical dimensions: challenges in novel drug development, insights from evidence-based medicine, and commercialization strategies for gout treatment.
We cordially invite you to join us live on May 17 as we work together to accelerate the globalization of China’s innovative drugs. See you online!
For more details, please click here.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 